ライフサイエンスコーパス: teduglutide

1 f weaning from parenteral nutrition while on teduglutide.

2 ctive but expensive intestinotrophic peptide teduglutide.

3 ents with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) o

4 , 14 women) to receive subcutaneous doses of teduglutide 4 mg or placebo (2:1 ratio; 23:13) once dail

5 ere observed on Day 10 in subjects receiving teduglutide 4 mg versus subjects receiving placebo.

6 Teduglutide 4 mg/day for 10 days does not affect gastric

7 Teduglutide, a glucagon-like peptide 2 analogue, might r

8 Teduglutide, a recombinant analog of human glucagon-like

9 with SBS support the safety and efficacy of teduglutide as an aid to parenteral nutrition weaning.

10 Teduglutide becomes economically reasonable only if its

11 uality-adjusted life years (QALYs)] of using teduglutide compared with offering intestinal transplant

12 In the base scenario, teduglutide cost $949,910/QALY gained.

13 ring only intestinal transplantation, adding teduglutide cost ${\$}$124,353/QALY gained.

14 In 1-way sensitivity analyses, only reducing teduglutide cost decreased the cost/QALY gained to below

15 Specifically, teduglutide cost would need to be reduced by >65% for it

16 Teduglutide could become a novel combination partner for

17 Never using teduglutide created an opportunity cost of over ${\$}$10

18 Teduglutide does not meet a traditional cost-effectivene

19 At its current price, teduglutide does not provide a cost-effective addition t

20 ohort studies, and 3) a prospective study of teduglutide effectiveness in parenteral nutrition-depend

21 If clinical data based on the study of teduglutide effectiveness in parenteral nutrition-depend

22 Nevertheless, the varying concentrations of teduglutide efficacy leave a degree of uncertainty in th

23 ed for parenteral support was greater in the teduglutide group (21/39 [54%]) than in the placebo grou

24 re were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (

25 eduction in parenteral support volume in the teduglutide group was 4.4 +/- 3.8 L/wk (baseline 12.9 +/

26 Teduglutide had an intermediate effect on patients in gr

27 identify characteristics of patients in whom teduglutide has the largest effects on parenteral suppor

28 sis favored transplantation without offering teduglutide in 68% of iterations at a ${\$}$100,000/QALY

29 dy evaluated the cost-effectiveness of using teduglutide in conjunction with offering intestinal tran

30 The effects of mitogenic stimulation with teduglutide in patients with short bowel syndrome might

31 Teduglutide in treating patients with SBS-IF meets the t

32 dy evaluated the cost-effectiveness of using teduglutide in US adult patients with short bowel syndro

33 Teduglutide increased bromodeoxyuridine-positive cells v

34 Teduglutide increased Caco-2 proliferation but tended to

35 The MTS assay demonstrated that teduglutide increased cell numbers by a mean (SD) of 10%

36 Teduglutide increased plasma concentrations of citrullin

37 Teduglutide induces a significant SB wall thickness incr

38 Teduglutide is a novel therapy that promotes intestinal

39 Teduglutide is a recombinant analogue of human glucagonl

40 No teduglutide is associated with 1,236,816 euro and 2.24 Q

41 Under the base case assumption, teduglutide is associated with costs of 2,296,311 euro p

42 the intestinal mucosa, and a GLP-2R agonist, teduglutide, is now used for augmentation of energy abso

43 ihood of reduced PN days per week when using teduglutide, leading to greater quality of life and lowe

44 tinuation was similar between patients given teduglutide (n = 2) and placebo (n = 3).

45 tyl glucosamine (n = 24), (iii) subcutaneous teduglutide (n = 26), (iv) budesonide (n = 25) or (v) st

46 The effects of teduglutide on absolute parenteral support volume were s

47 ve of this study was to assess the effect of teduglutide on gastric emptying of liquids in healthy su

48 However, the effects of teduglutide on parenteral support vary among patients.

49 ata from a phase III study of the effects of teduglutide on patients with SBS, we associated reduced

50 tabolism classification system, who received teduglutide or placebo between November 25, 2008, and Ja

51 etaminophen absorption in subjects receiving teduglutide or placebo.

52 Cells were exposed to teduglutide or vehicle control.

53 life years (QALYs), and life years (LYs)] of teduglutide plus best supportive care compared with best

54 Teduglutide reduced the mean (SD) expression of villin b

55 Teduglutide reduced the primary endpoint of biomarkers o

56 Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refr

57 med a prospective study to determine whether teduglutide reduces parenteral support in patients with

58 Teduglutide (TED) is a glucagon-like peptide 2 analogue

59 However, teduglutide therapy was cost-saving in 13% of model iter

60 BACKGROUND & AIMS: Clinical studies showed teduglutide to increase urine production and reduce need

61 ndrome might be greater if the more numerous teduglutide-treated cells could be stimulated toward a m

62 436 mL/d; P = .0112) but also compared with teduglutide-treated patients in group 2 (reduction of 35

63 ted parenteral support volume reduction with teduglutide treatment and baseline parenteral support vo

64 Twenty-four weeks of teduglutide treatment was generally well tolerated in pa

65 robabilistic sensitivity analysis favored no teduglutide use in 80% of iterations at a $100,000/QALY

66 Teduglutide use in pediatric patients with short bowel s

67 ars, or QALYs) of treatment compared with no teduglutide use, with a presumed starting age of 40 y.

68 Fourteen patients (8%) were treated with teduglutide, with no significant difference between age